Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3Kδ-inhibitors in Respiratory Models of TH2 and TH1 Inflammation.

McLeod RL, Gil MA, Chen D, Cabal A, Katz J, Methot J, Woodhouse JD, Dorosh L, Geda P, Mehta K, Cicmil M, Baltus GA, Bass A, Houshyar H, Caniga M, Yu H, Gervais F, Alves S, Shah S.

J Pharmacol Exp Ther. 2019 Feb 25. pii: jpet.118.252551. doi: 10.1124/jpet.118.252551. [Epub ahead of print]

2.

Anticoagulants oraux directs.

Leclerc J, Sanctuaire A, Nadon N, Méthot J.

Perspect Infirm. 2018 Sep-Oct;15(4):38-44. French. No abstract available.

PMID:
30204354
3.

Reconsidering non-traditional export agriculture and household food security: A case study in rural Guatemala.

Méthot J, Bennett EM.

PLoS One. 2018 May 24;13(5):e0198113. doi: 10.1371/journal.pone.0198113. eCollection 2018.

4.

Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.

Gaudet D, Stroes ES, Méthot J, Brisson D, Tremblay K, Bernelot Moens SJ, Iotti G, Rastelletti I, Ardigo D, Corzo D, Meyer C, Andersen M, Ruszniewski P, Deakin M, Bruno MJ.

Hum Gene Ther. 2016 Nov;27(11):916-925. Epub 2016 Jul 13.

PMID:
27412455
5.

Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.

Lim J, Kelley EH, Methot JL, Zhou H, Petrocchi A, Chen H, Hill SE, Hinton MC, Hruza A, Jung JO, Maclean JK, Mansueto M, Naumov GN, Philippar U, Raut S, Spacciapoli P, Sun D, Siliphaivanh P.

J Med Chem. 2016 Jul 14;59(13):6501-11. doi: 10.1021/acs.jmedchem.6b00708. Epub 2016 Jul 1.

PMID:
27329786
6.

Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.

Fischer C, Zultanski SL, Zhou H, Methot JL, Shah S, Hayashi I, Hughes BL, Moxham CM, Bays NW, Smotrov N, Hill AD, Pan BS, Wu Z, Moy LY, Tanga F, Kenific C, Cruz JC, Walker D, Bouthillette M, Nikov GN, Deshmukh SV, Jeliazkova-Mecheva VV, Diaz D, Michener MS, Cook JJ, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3488-94. doi: 10.1016/j.bmcl.2015.07.003. Epub 2015 Jul 9.

PMID:
26212776
7.

Potent benzoazepinone γ-secretase modulators with improved bioavailability.

Methot JL, Fischer C, Li C, Rivkin A, Ahearn SP, Brown WC, Kattar S, Kelley E, Mampreian DM, Schell A, Rosenau A, Zhou H, Ball R, Deshmukh SV, Jeliazkova-Mecheva VV, Diaz D, Moy LY, Kenific CM, Moxham C, Shah S, Nuthall H, Szewczak AA, Hill A, Hughes B, Smotrov N, Munoz B, Miller TA, Shearman MS.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3495-500. doi: 10.1016/j.bmcl.2015.06.032. Epub 2015 Jun 15.

PMID:
26142947
8.

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

Methot JL, Hoffman DM, Witter DJ, Stanton MG, Harrington P, Hamblett C, Siliphaivanh P, Wilson K, Hubbs J, Heidebrecht R, Kral AM, Ozerova N, Fleming JC, Wang H, Szewczak AA, Middleton RE, Hughes B, Cruz JC, Haines BB, Chenard M, Kenific CM, Harsch A, Secrist JP, Miller TA.

ACS Med Chem Lett. 2014 Jan 2;5(4):340-5. doi: 10.1021/ml4004233. eCollection 2014 Apr 10.

9.

Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.

Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, Methot J, Petry H, Gaudet D.

Hum Gene Ther. 2014 Mar;25(3):180-8. doi: 10.1089/hum.2013.169. Epub 2014 Feb 28.

10.

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.

Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.

Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.

11.

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.

Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S.

Gene Ther. 2013 Apr;20(4):361-9. doi: 10.1038/gt.2012.43. Epub 2012 Jun 21.

12.

Gene therapy for lipoprotein lipase deficiency.

Gaudet D, Méthot J, Kastelein J.

Curr Opin Lipidol. 2012 Aug;23(4):310-20. doi: 10.1097/MOL.0b013e3283555a7e. Review.

PMID:
22691709
13.

Triazoloamides as potent γ-secretase modulators with reduced hERG liability.

Fischer C, Zultanski SL, Zhou H, Methot JL, Shah S, Nuthall H, Hughes BL, Smotrov N, Hill A, Szewczak AA, Moxham CM, Bays N, Middleton RE, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2012 May 1;22(9):3140-6. doi: 10.1016/j.bmcl.2012.03.054. Epub 2012 Mar 21.

PMID:
22497762
14.

Salivary pH as a marker of plasma adiponectin concentrations in Women.

Tremblay M, Loucif Y, Methot J, Brisson D, Gaudet D.

Diabetol Metab Syndr. 2012 Feb 3;4(1):4. doi: 10.1186/1758-5996-4-4.

15.

On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs).

Méthot J, Brisson D, Gaudet D.

Clin Trials. 2012 Apr;9(2):265-71. doi: 10.1177/1740774511431280. Epub 2012 Jan 5.

PMID:
22222352
16.

Triazoles as γ-secretase modulators.

Fischer C, Zultanski SL, Zhou H, Methot JL, Brown WC, Mampreian DM, Schell AJ, Shah S, Nuthall H, Hughes BL, Smotrov N, Kenific CM, Cruz JC, Walker D, Bouthillette M, Nikov GN, Savage DF, Jeliazkova-Mecheva VV, Diaz D, Szewczak AA, Bays N, Middleton RE, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2011 Jul 1;21(13):4083-7. doi: 10.1016/j.bmcl.2011.04.089. Epub 2011 May 4.

PMID:
21616665
17.

Contribution of the ulnar digits to grip strength.

Methot J, Chinchalkar SJ, Richards RS.

Can J Plast Surg. 2010 Spring;18(1):e10-4.

18.

Etiology and risk of lactescent plasma and severe hypertriglyceridemia.

Tremblay K, Méthot J, Brisson D, Gaudet D.

J Clin Lipidol. 2011 Jan-Feb;5(1):37-44. doi: 10.1016/j.jacl.2010.11.004. Epub 2010 Nov 18.

PMID:
21262505
19.

Contribution of adiponectin to the cardiometabolic risk of postmenopausal women with loss-of-function lipoprotein lipase gene mutations.

Loucif Y, Méthot J, Tremblay K, Brisson D, Gaudet D.

Menopause. 2011 May;18(5):558-62. doi: 10.1097/gme.0b013e3181fca1d4.

PMID:
21252727
20.

The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.

Smith J, Ferland A, Méthot J, Brassard P, Lacroix S, Poirier P, Cianflone K.

Nutr Metab Cardiovasc Dis. 2012 Jun;22(6):495-502. doi: 10.1016/j.numecd.2010.08.008. Epub 2011 Jan 17.

PMID:
21247745
21.

Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.

Brisson D, Méthot J, Tremblay K, Tremblay M, Perron P, Gaudet D.

Pharmacogenet Genomics. 2010 Dec;20(12):742-7. doi: 10.1097/FPC.0b013e328340095e.

PMID:
21217359
22.

Obesity: how to define central adiposity?

Méthot J, Houle J, Poirier P.

Expert Rev Cardiovasc Ther. 2010 May;8(5):639-44. doi: 10.1586/erc.10.38. No abstract available.

PMID:
20450297
23.

Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.

Gaudet D, de Wal J, Tremblay K, Déry S, van Deventer S, Freidig A, Brisson D, Méthot J.

Atheroscler Suppl. 2010 Jun;11(1):55-60. doi: 10.1016/j.atherosclerosissup.2010.03.004. Epub 2010 Apr 27. Review.

PMID:
20427244
24.

Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.

Kattar SD, Surdi LM, Zabierek A, Methot JL, Middleton RE, Hughes B, Szewczak AA, Dahlberg WK, Kral AM, Ozerova N, Fleming JC, Wang H, Secrist P, Harsch A, Hamill JE, Cruz JC, Kenific CM, Chenard M, Miller TA, Berk SC, Tempest P.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72. doi: 10.1016/j.bmcl.2008.12.083. Epub 2008 Dec 25.

PMID:
19138845
25.

SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Methot JL, Hamblett CL, Mampreian DM, Jung J, Harsch A, Szewczak AA, Dahlberg WK, Middleton RE, Hughes B, Fleming JC, Wang H, Kral AM, Ozerova N, Cruz JC, Haines B, Chenard M, Kenific CM, Secrist JP, Miller TA.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. doi: 10.1016/j.bmcl.2008.10.052. Epub 2008 Oct 14.

PMID:
18951790
26.

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Methot JL, Chakravarty PK, Chenard M, Close J, Cruz JC, Dahlberg WK, Fleming J, Hamblett CL, Hamill JE, Harrington P, Harsch A, Heidebrecht R, Hughes B, Jung J, Kenific CM, Kral AM, Meinke PT, Middleton RE, Ozerova N, Sloman DL, Stanton MG, Szewczak AA, Tyagarajan S, Witter DJ, Secrist JP, Miller TA.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8. doi: 10.1016/j.bmcl.2007.12.031. Epub 2008 Jan 7.

PMID:
18182289
27.

The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.

Hamblett CL, Methot JL, Mampreian DM, Sloman DL, Stanton MG, Kral AM, Fleming JC, Cruz JC, Chenard M, Ozerova N, Hitz AM, Wang H, Deshmukh SV, Nazef N, Harsch A, Hughes B, Dahlberg WK, Szewczak AA, Middleton RE, Mosley RT, Secrist JP, Miller TA.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5300-9. Epub 2007 Aug 16.

PMID:
17761416
28.

The ACE-DD genotype is associated with endothelial dysfunction in postmenopausal women.

Méthot J, Hamelin BA, Arsenault M, Bogaty P, Plante S, Poirier P.

Menopause. 2006 Nov-Dec;13(6):959-66.

PMID:
17003740
29.

ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women.

Méthot J, Hamelin BA, Bogaty P, Arsenault M, Plante S, Poirier P.

Int J Cardiol. 2005 Dec 7;105(3):308-14.

PMID:
16274774
30.

Does hormonal status influence the clinical presentation of acute coronary syndromes in women?

Méthot J, Hamelin BA, Bogaty P, Arsenault M, Plante S, Poirier P.

J Womens Health (Larchmt). 2004 Jul-Aug;13(6):695-702.

PMID:
15333284
31.
32.

Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women.

Hamelin BA, Méthot J, Arsenault M, Pilote S, Poirier P, Plante S, Bogaty P.

Am J Med. 2003 May;114(7):599-602. No abstract available.

PMID:
12753884
33.

Synthetic studies toward diazonamide A. A novel approach for polyoxazole synthesis.

Wipf P, Methot JL.

Org Lett. 2001 May 3;3(9):1261-4.

PMID:
11348209
34.

Total synthesis and stereochemical revision of (+)-aeruginosin 298-A.

Wipf P, Methot JL.

Org Lett. 2000 Dec 28;2(26):4213-6.

PMID:
11150202
35.

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.

Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J, Turgeon J.

Clin Pharmacol Ther. 2000 May;67(5):466-77.

PMID:
10824625
36.

[Controlled hypotension in thoracic surgery; clinical study and electrocardiography of 100 cases and 100 controls].

LONGTIN J, LONGTIN L, BOUSQUET E, METHOT JP.

Union Med Can. 1954 Jun;83(6):625-8. Undetermined Language. No abstract available.

PMID:
13179340

Supplemental Content

Loading ...
Support Center